<?xml version="1.0" encoding="UTF-8"?>
<p>Although recent advances have been made in propagating prudent antibiotic use through harmonised treatment guidance [
 <xref rid="r5" ref-type="bibr">5</xref>-
 <xref rid="r7" ref-type="bibr">7</xref>], historically, differences in clinical practices exist between EU countries, which is also reflected in differences in the nationally approved product information of antibiotics across Europe. As provided in the EU legislation relating to medicinal products for human use [
 <xref rid="r8" ref-type="bibr">8</xref>], the referral is a post-authorisation procedure that may be initiated under specific conditions such as disagreements among Member States on the use of the medicine or concerns relating to the quality, safety or efficacy of a medicine or a class of medicines. The outcome of a referral may lead to maintenance or regulatory actions such as revocation, suspension or variation to the terms of the marketing authorisations. A variation may cover changes in therapeutic indication, dose recommendations or raising healthcare professionals’ and patients’ awareness regarding particular risks. 
</p>
